Therakind’s DriDose® Dry Powder Intranasal Device Delivers Vaccine
DriDose® has potential to improve adherence in difficult-to-treat patients
March 28 2023 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces the successful results of a pre-clinical immunogenicity study of DriDose®, Therakind’s novel dry powder intranasal device, with Mymetics’ SARS-CoV-2 nasal powder vaccine candidate.
In the pre-clinical study conducted by Mymetics SA, DriDose® has demonstrated efficient delivery of the Mymetics’ SARS-CoV-2 nasal powder vaccine candidate. When compared to the standard nasal applicator used at Mymetics, DriDose® delivered comparable amounts of nasal powder, resulting in comparable serum antibody titres. DriDose® also demonstrated no detectable health or behaviour changes in the pre-clinical model.
DriDose® is a Dry Powder Intranasal Device designed for non-invasive and painless delivery of a dry powder drug formulation. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use in a single-handed manner with no specialist training or sterile technique required. The device can be used by physicians, caregivers or patients providing multiple market opportunities. Furthermore, the device is intended to be suitable for administration to unconscious patients as no active inhaling technique is required. The dry powder formulation also enables a long shelf life and potentially avoids cold chain requirements.
Susan Conroy, CEO of Therakind, said: “We are delighted with the results of this initial immunogenicity study with a vaccine. DriDose® offers the potential to deliver vaccines without the use of needles. DriDose® has an important role to play, particularly for difficult-to-treat patients, where treatment adherence is low. We are now progressing additional DriDose® development studies as well as advancing our multi-dose device which offers a low cost, low impact nasal delivery technology.”
Mario Amacker, Head Manufacturing and Quality of Mymetics, said: “I am very pleased to see that the DriDose® applicator delivered comparable immunogenicity and safety results to our standard applicator in this pre-clinical study of our intra-nasal powder vaccine.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche medicines in difficult-to-treat markets including paediatric and geriatric patient groups.
Our proprietary pipeline is focused on improving medicine adherence through more patient friendly dosing options and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. DriDose®, our intranasal device for the delivery of a dry powder drug formulation is available for co-development. We have also developed a device that is adapted for nasal delivery in a preclinical setting.
To date we have developed and obtained marketing authorisations for three paediatric products, with Jylamvo, our European approved oral methotrexate solution for treating rheumatological and dermatological diseases and acute lymphoblastic leukaemia, also licensed for adults.
To find out more, please visit www.therakind.com
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline under development, among which are Covid-19, HIV-1/AIDS and malaria, and collaborative projects in the cancer immunotherapy.
Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on both the mucosal and serum immune response. Virosomes have shown to trigger also specific T-cell responses. For further information, please visit www.mymetics.com.
